Resources Repository
-
GuidelinesPublication 2014EPA Guidelines for Preparing Economic Analyses
The US Environmental Protection Agency (EPA) Guidelines for Preparing Economic Analyses provide a framework for …
The US Environmental Protection Agency (EPA) Guidelines for Preparing Economic Analyses provide a framework for assessing the impacts of environmental regulations and policies that has been extensively peer-reviewed and is widely-applied both within and outside of the agency. The Guidelines discuss: (1) statutory and executive order requirements for conducting economic analyses; (2) identifying the need for policy action; (3) regulatory and non-regulatory approaches to pollution control; (4) baseline definition; (5) discounting future benefits and costs;…
Benefit-Cost Analysis | Decision Analysis | Preferences/Values | Priority Setting/Ethics | Environmental Health | Policy/Regulation | Climate/Environment | Government/Law | North America | Critical Thinking/Analysis -
GuidelinesPublication 2014Methods for Economic Evaluation Project
This report details the work of the Methods for Economic Evaluation Project (MEEP), which aims …
This report details the work of the Methods for Economic Evaluation Project (MEEP), which aims to promote a consistency in the methods used for economic evaluations. The report is targeted especially at low and middle-income countries (LMICs). The Bill and Melinda Gates Foundation is a major funder of health economic evaluations in LMICs, but there is substantial variation in the methods used and the quality of the analyses produced. The report drew on expertise from…
Benefit-Cost Analysis | Cost-Effectiveness Analysis | Priority Setting/Ethics | Costing Methods | Climate/Environment | Education/Labor | Health/Medicine | Global -
GuidelinesPublication 2013Guide to the Methods of Technology Appraisal 2013
The National Institute for Health and Care Excellence (NICE, or the Institute) provides guidance to …
The National Institute for Health and Care Excellence (NICE, or the Institute) provides guidance to the NHS in England on the clinical and cost effectiveness of selected new and established technologies. The Institute undertakes appraisals of health technologies at the request of the Department of Health. Guidance produced by the Institute on health technologies is also applied selectively in Northern Ireland, Scotland and Wales. The purpose of this document is to provide an overview of…
Technology Assessment | Cost-Effectiveness Analysis | Priority Setting/Ethics | Health Systems | Policy/Regulation | Government/Law | Health/Medicine | Europe -
GuidelinesPublication 2011HPV Vaccine Introduction in LMIC's: Guidance on the Use of Cost-Effectiveness Models
This article is a literature review of HPV vaccination models suitable for low-income and middle-income …
This article is a literature review of HPV vaccination models suitable for low-income and middle-income country use to provide information about the feasibility of using such models in a developing country setting. The authors evaluated models in terms of their capacity, requirements, limitations and comparability. Their literature review identified six HPV vaccination models suitable for low-income and middle-income country use and representative of the literature in terms of provenance and model structure. Each model was…
Cost-Effectiveness Analysis | Calibration/Validation | Mathematical Models | Infectious Diseases | Chronic Disease/Risk | Health Systems | Clinical Care | Health/Medicine | Science/Technology | Global -
ReportPublication 2022Investment Case for New Tuberculosis Vaccines
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis (TB) vaccine will …
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis (TB) vaccine will save lives, fight antimicrobial resistance, advance health equity, improve economic growth, and bring a substantial return on investment. This World Health Organization (WHO) report describes the full value proposition for new TB vaccines. These analyses articulate the broader economic impacts of new TB vaccines to guide global stakeholders when making investment decisions for novel TB vaccines and to plan for…
Cost-Effectiveness Analysis | Infectious Diseases | Economics/Finance | Health/Medicine | Global -
ReportPublication 2021Valuing COVID-19 Mortality and Morbidity Risks
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk …
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk reductions that builds on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. They review the differences between COVID-19 mortality risks and the types of risks that are more commonly studied, and find that the impacts of these differences on the value of mortality risk reductions (the value per statistical life, VSL) are uncertain. They…
Benefit-Cost Analysis | Preferences/Values | Infectious Diseases | Policy/Regulation | Government/Law | North America -
ReportPublication 2019Reference Case Guidelines for BCA in Global Health and Development
The "Benefit‐Cost Analysis Reference Case: Principles, Methods, and Standards" project, with support from the Bill …
The "Benefit‐Cost Analysis Reference Case: Principles, Methods, and Standards" project, with support from the Bill & Melinda Gates Foundation, culminates in the final “Reference Case Guidelines for Benefit-Cost Analysis in Global Health and Development.” These guidelines aim to facilitate the utilization and effectiveness of benefit-cost analysis by providing clarity on essential concepts, aiding implementation, and suggesting default values for key parameters, along with options for standardized sensitivity analysis. Targeted at practitioners with economic evaluation expertise…
Benefit-Cost Analysis | Health/Medicine | Global -
ReportPublication 2016DCP3: Reproductive, Maternal, Newborn, and Child Health
This report from the World Bank is the second volume of the Disease Control Priorities, …
This report from the World Bank is the second volume of the Disease Control Priorities, Third Edition (DCP3) series. It focuses primarily on maternal conditions, childhood illnesses, and malnutrition, addressing topics from maternal mortality and morbidity, to acute illness and undernutrition in children under five, to the transition to older childhood and the illnesses that accompany this transition. The Disease Control Priorities Network (DCP) promotes and supports the use of economic evaluation for priority setting…
Cost-Effectiveness Analysis | Costing Methods | Health Outcomes | Evidence Synthesis | Maternal/Reproductive Health | Child/Nutrition | Health Systems | Global Governance | Economics/Finance | Health/Medicine | Global -
ReportPublication 2017DCP3: Child and Adolescent Health and Development
This report from the World Bank is the eighth volume of the Disease Control Priorities, …
This report from the World Bank is the eighth volume of the Disease Control Priorities, Third Edition (DCP3) series and focuses on the health and well-being of children and adolescents, ages 5 to 21, worldwide. It provides estimates of mortality and morbidity among youth, examines the impact of interventions during that period on health and development, features successful community- and school-based health and nutrition interventions, reports on platforms that promote early childhood development, and highlights…
Cost-Effectiveness Analysis | Costing Methods | Health Outcomes | Evidence Synthesis | Child/Nutrition | Social Determinants | Global Governance | Economics/Finance | Health/Medicine | Global